Trial Profile
A study evaluating efficacy of oral direct acting antivirals for treatment of chronic hepatitis/cirhhosis due to hepatitis C virus infection: real-life experience of the Sicily Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Oct 2020
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms RESIST HCV
- 29 Aug 2020 Results (n=4087) presented at The International Liver Congress 2020
- 10 Jul 2017 New trial record